Dysmenorrhea – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Dysmenorrhea Market Outlook

Thelansis’s “Dysmenorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Dysmenorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Dysmenorrhea Overview

Dysmenorrhea is a Greek term for “painful monthly bleeding". It can be classified as primary and secondary dysmenorrhea. Primary dysmenorrhea is a lower abdominal pain during the menstrual cycle, not associated with other diseases or pathology. In contrast, secondary dysmenorrhea is usually associated with other pathology inside or outside the uterus. Dysmenorrhea is a common complaint among women during their reproductive age. It is associated with significant emotional, psychological, and functional health impacts. During menstruation, chemicals called "prostaglandins" form in the lining of the uterus. They cause muscle contractions in the uterus, which can trigger pain and decrease blood flow and oxygen to the uterus. Similar to labor pains, these contractions can cause significant pain and discomfort. Prostaglandins may also contribute to other menstrual symptoms, such as nausea and diarrhea.

Associated risk factors are:

• Age
• Smoking
• Attempts to lose weight
• Higher body mass index
• Depression/anxiety
• Earlier age at menarche
• Nulliparity
• Longer and heavier menstrual flow
• Family history of dysmenorrhea
• Disruption of social networks

The pain of dysmenorrhea is crampy and usually located in the lower abdomen; some people also have severe pain in the back or thighs. The pain usually begins just before or as menstrual bleeding begins and gradually improves over one to three days. The pain usually occurs intermittently and can range from mild to disabling. Other symptoms accompanying cramping include nausea, diarrhea, dizziness, fatigue, headache, or a flu-like feeling. The pathophysiology of primary dysmenorrhea is not well understood. Nevertheless, the identified cause is due to the hypersecretion of the prostaglandins from the uterine inner lining. Prostaglandin F2alpha (PGF-2a) and Prostaglandin PGF 2 increase the uterine tone and also causes high-amplitude contractions of the uterus. Also, vasopressin has been linked to primary dysmenorrhea. Vasopressin increases uterine contractility and can cause ischemic pain due to its vasoconstriction effects. Progesterone levels drop before menstruation, increasing PG production and triggering dysmenorrhea. Endometriosis and adenomyosis are the most common causes of secondary dysmenorrhea in premenopausal women. Secondary dysmenorrhea complication varies depending on the etiology. Complications may include infertility, pelvic organ prolapse, heavy bleeding, and anemia.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: